+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Verona Pharma Plc (VRNA) - Financial and Strategic SWOT Analysis Review

Verona Pharma Plc (VRNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company's operations and business divisions.
  • Corporate strategy - Analyst's summarization of the company's business strategy.
  • SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives' employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Verona Pharma Plc (Verona Pharma) is a clinical-stage biopharmaceutical company that focuses on the development and marketing of therapies for the treatment of respiratory diseases. The company's lead investigating candidate, ensifentrine, a bronchodilator/anti-inflammatory agent intended for the treatment of chronic obstructive pulmonary disease (COPD) in Phase III clinical trials. Additionally the company is evaluating ensifentrine for the treatment of cystic fibrosis and asthma under its Phase II trials. Verona Pharma is headquartered in London, the UK.

Verona Pharma Plc Key Recent Developments

  • May 09, 2023: Verona Pharma reports first quarter 2023 financial results and provides corporate update
  • Apr 25, 2023: Verona Pharma to report Q1 2023 financial results and provide corporate update
  • Feb 21, 2023: Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
  • Nov 09, 2022: Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Verona Pharma Plc - Key Facts
  • Verona Pharma Plc - Key Employees
  • Verona Pharma Plc - Key Employee Biographies
  • Verona Pharma Plc - Major Products and Services
  • Verona Pharma Plc - History
  • Verona Pharma Plc - Company Statement
  • Verona Pharma Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Verona Pharma Plc - Business Description
  • R&D Overview
  • Verona Pharma Plc - Corporate Strategy
  • Verona Pharma Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Verona Pharma Plc - Strengths
  • Verona Pharma Plc - Weaknesses
  • Verona Pharma Plc - Opportunities
  • Verona Pharma Plc - Threats
  • Verona Pharma Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Verona Pharma Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 09, 2023: Verona Pharma reports first quarter 2023 financial results and provides corporate update
  • Apr 25, 2023: Verona Pharma to report Q1 2023 financial results and provide corporate update
  • Feb 21, 2023: Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
  • Nov 09, 2022: Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
  • Aug 24, 2022: Verona Pharma strengthens commercialization leadership team
  • Jul 29, 2022: Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update
  • May 04, 2022: Verona Pharma Announces May 2022 Investor Conference Participation
  • May 03, 2022: Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update
  • Mar 14, 2022: James Brady Joins Verona Pharma as Non-Executive Director
  • Jan 04, 2022: Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Verona Pharma Plc, Key Facts
  • Verona Pharma Plc, Key Employees
  • Verona Pharma Plc, Key Employee Biographies
  • Verona Pharma Plc, Major Products and Services
  • Verona Pharma Plc, History
  • Verona Pharma Plc, Subsidiaries
  • Verona Pharma Plc, Key Competitors
  • Verona Pharma Plc, Ratios based on current share price
  • Verona Pharma Plc, Annual Ratios
  • Verona Pharma Plc, Interim Ratios
  • Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Verona Pharma Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Verona Pharma Plc, Performance Chart (2018 - 2022)
  • Verona Pharma Plc, Ratio Charts
  • Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Verona Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • GSK plc
  • Novartis AG
  • AstraZeneca Plc
  • Chiesi Farmaceutici SpA
  • Boehringer Ingelheim International GmbH
  • Vernalis R&D Ltd